Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ESBATech has achieved high concentrations of its antibody fragments in all segments of the eye with topical delivery via eye drops. These data were confirmed in several independent preclinical in vivo tests.
Subscribe to our email newsletter
Anticipated therapeutic concentrations of ESBATech’s antibody fragments were observed in the anterior chamber (front of the eye) and in the posterior segments (back of the eye) including vitreous humour, retina, and choroid. ESBATech’s lead antibody fragment ESBA105 is a TNFa antagonist that is scheduled to enter clinical development later in 2008.
Dominik Escher, CEO of ESBATech, said: “We believe that with our highly stable and monomeric single-chain antibody fragments, we now meet the protein requirements that allow for sufficient delivery of immune binders into all segments of the eye via eye drops.”